EUCTR2016-005010-22-HR进行中（未招募）1 期
A Randomized, Open-Label, Cross-over Study to Assess the Relative Bioavailability of LY03004 and EU Risperdal® Consta® at 50 mg Following Multiple Intramuscular Injections in Stable Patients with Schizophrenia - Relative bioavailability study of LY03004 at steady-state
anjing Luye Pharmaceutical Co., Ltd.0 个研究点目标入组 250 人开始时间: 2019年5月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Only subjects presenting the following criteria will be enrolled in the present study:
- •[1] Male or female patients aged 18 to 65 years old, inclusive;
- •[2] Patients must have a DSM-IV-TR diagnosis of schizophrenia based on the Mini-International Neuropsychiatric Interview (MINI). The duration of the
- •illness must be at least 2 years prior to screening;
- •[3] Patients must have an identified support person (e.g. family member, case worker, social worker) considered reliable by the investigator to help ensure compliance with study treatment and visits and to alert staff of any issues of
- •[4] Patients must have a stable place of residence for the 3 months prior to screening;
- •[5] Patients must not have been either hospitalized for worsening of schizophrenic symptoms or judged by the investigator as having significant
- •exacerbation of schizophrenic symptoms during the 3 months prior to screening;
- •[6] Patients must be on a stable dose of oral antipsychotic medication(s) or on Risperidone depot 50 mg for at least 4 weeks prior to screening, AND
- •clinically stable based on clinical assessments and having a Positive and Negative Syndrome Scale (PANSS) total score of =70 as well as a subtotal
- •score of HATE (hostility, anxiety, tension and excitement) <16 within the PANSS interview at screening and baseline visits;
- •[7] Patients with a Body Mass Index in range of 18.0 to 38.0, inclusive;
- •[8] Patients with an Informed Consent Form signed by the patient;
- •[9] Female patients must have a negative serum pregnancy test at screening;
- •[10] Female patients must be either postmenopausal [postmenopausal women defined as one of the following: more than 6 months amenorrhea in patients =55 years, OR more than 18 months amenorrhea in patients <55 years, OR baseline serum FSH >35 IU/l in patients <55 years and less than 18
- •months amenorrhea, OR surgical menopause for more than 4 weeks] or woman of childbearing potential [A woman of childbearing potential is
- •defined as a premenopausal female capable of becoming pregnant. This includes women on oral, injectable, or mechanical contraception; women
- •who are single; women whose husbands have been vasectomized or whose husbands have received or are utilizing mechanical contraceptive
- •[11] Women of childbearing potential must be practicing or agree to practice an effective method of birth control if they are sexually active before study entry, during the study and two months after the end of the study by using an acceptable method of contraception. Acceptable methods of birth control must be used for at least 30 days prior to the use of study drug. Acceptable methods of birth control are oral, injected, vaginal or patch contraceptive and IUD (intrauterine device);
- •[12] Sexually active male subjects must use condoms as contraception method for at least 30 days prior to the use of study drug, during the participation in the trial, and until 2 months after the end of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[1] Patients with a primary and active DSM-IV-TR diagnosis other than schizophrenia;
- •[2] Patients who received paliperidone palmitate within 10 months prior to screening. Oral risperidone tolerability test should be performed in those
- •patients without documented evidence of tolerability to risperidone;
- •[3] Patients who are non-responders to risperidone or paliperidone;
- •[4] Patients who pose a significant risk of a suicide attempt based on history or the investigator’s judgment, or are at imminent risk of suicide or violent behavior based on the investigator’s clinical assessment;
- •[5] Patients with a history of neuroleptic malignant syndrome or tardive dyskinesia, or a history of severe akathisia or extra-pyramidal reactions
- •such as dystonia with previous use of risperidone or other neuroleptic treatments;
- •[6] Patients with uncontrolled diabetes mellitus, or a HbA1c level =7%, or with diabetes mellitus requiring use of insulin. Patients with newly diagnosed Type 2 diabetes during the screening period are excluded;
- •[7] Patients with a history of or who are currently diagnosed as having epilepsy or convulsion disorders;
- •[8] Patients who have had electroconvulsive therapy within the past 2 months prior to screening;
- •[9] Patients who used medication known to be a potent or moderate inhibitor of CYP 2D6 or a potent inducer of CYP 3A4 within 2 weeks or 5 PK half-lives, whichever is longer, prior to screening;
- •[10] Patients with a history of an allergic reaction to risperidone or to the excipients of LY03004, or show an allergic reaction to oral risperidone
- •tolerability test;
- •[11] Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the exception of caffeine or nicotine in the past 6 months
- •prior to screening, or test positive for a drug of abuse or alcohol at screening or baseline (except positive findings that can be accounted for by
- •documented prescription use prescribed by a treating physician as a part of the treatment for the patient’s psychiatric illness);
- •[12] Patients with a history of, or current clinically relevant cardiac arrhythmia, cardiovascular disease, thyrotoxicosis, parkinsonism, or hemorrhagic
- •[13] Patients who have a history of malignancy within the past five years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer;
- •[14] Patients who have received a MAO inhibitor within 30 days prior to screening;
- •[15] Female patients who are pregnant, or tested positive for pregnancy at screening, or are breastfeeding, or are of childbearing potential without
- •adequate use of contraception;
- •[16] Patients who have any uncontrolled, unstable clinically relevant medical condition (e.g. hepatic, renal, cardiovascular, endocrine, respiratory,
- •hematologic, immunologic or cerebrovascular disease), or other medical condition, which in the judgment of the investigator would interfere with the
- •subject's ability to participate in the study;
- •[17] Patients with a QTcF interval greater than 450 msec for males and 470 msec for females, or other clinically significant ECG findings in the opinion
- •of the investigator;
- •[18] Patients who have any one of the following three conditions: (i) clinically significant liver dysfunction, (ii) HBsAg positive, (iii) a serum alanine
- •aminotransferase (ALT) or aspartate aminotransferase (AST) levels of > 2x upper limit of normal (ULN) range (if the ALT or AST levels are between 2x
- •– 3x ULN in the first screening test and the elevation may
研究者
相似试验
进行中（未招募）
不适用
A clinical study involving people with severe haemophilia A to look athow two different strengths of an experimental replacement factor VIII protein (known asrFVIIIFc) are processed by the body and how safe it is to take.Hemophilia AMedDRA version: 18.0Level: LLTClassification code 10053753Term: Hemophilia A without inhibitorsSystem Organ Class: 100000004850MedDRA version: 18.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2013-003013-18-GBBiogen Idec Research Ltd16
已完成
不适用
An open-label, randomized crossover study to evaluate the pharmacokinetics, bioavailability, bioequivalence, and food effect following administration of Oxybate Formulations in healthy subjects.NL-OMON41817Jazz Pharmaceuticals60
已完成
不适用
An open-label, randomized crossover study to evaluate the effect of ASP1941 on the pharmacokinetics, pharmacodynamics, safety and tolerability of glimepiride in healthy subjects and vice versa.NL-OMON34715Astellas Pharma26
已完成
不适用
A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammatioCOPDJPRN-UMIN000024905Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital25
已完成
不适用
Drug-drug Interaction Study(Lobeglitazone, Warfarin)Endocrine, nutritional and metabolic diseaseKCT0000999Chong Kun Dang24